SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine. Its orthobiologics products include demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to enhance bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company offers orthobiologics products in various forms, such as putties, pastes, strips, and resorbable mesh. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in minimally invasive, complex, deformity, and degenerative procedures. The company was incorporated in 2015 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone760-727-8399
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$131.81 million
Profitability
Miscellaneous
Employees327
OptionableOptionable
SeaSpine (NASDAQ:SPNE) Frequently Asked Questions
What is SeaSpine's stock symbol?
SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."
How were SeaSpine's earnings last quarter?
SeaSpine Holdings Corp (NASDAQ:SPNE) posted its quarterly earnings data on Thursday, May, 3rd. The medical equipment provider reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.03. The medical equipment provider had revenue of $33.18 million for the quarter, compared to analysts' expectations of $32.75 million. SeaSpine had a negative net margin of 22.60% and a negative return on equity of 30.81%. View SeaSpine's Earnings History.
When is SeaSpine's next earnings date?
What price target have analysts set for SPNE?
6 Wall Street analysts have issued 1 year target prices for SeaSpine's stock. Their predictions range from $17.00 to $23.00. On average, they anticipate SeaSpine's share price to reach $20.50 in the next twelve months. This suggests a possible upside of 24.8% from the stock's current price. View Analyst Price Targets for SeaSpine.
What is the consensus analysts' recommendation for SeaSpine?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SeaSpine.
What are Wall Street analysts saying about SeaSpine stock?
Here are some recent quotes from research analysts about SeaSpine stock:
- 1. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on SeaSpine and 12-month PT of $22. SPNE is a relatively small player (1% market share) in the spine market; however we think that its new product launches and an underappreciated, sizable orthobiologics business should help SPNE differentiate it from other spine companies of similar size. Given the size of the company and the inconsistent results post-spin, we think many investors have not been following the recent progress at the company. We believe SPNE will have to continue to execute and deliver on management’s expectation of exiting the year at high single digit or low double-digit growth to drive appreciation in the stock." (1/7/2019)
- 2. According to Zacks Investment Research, "SeaSpine Holdings Corporation is a medical technology company which focused on the design, development and commercialization of surgical solutions for the treatment of spinal disorders. The company also offers orthobiologics and spinal fusion hardware solutions. SeaSpine Holdings Corporation is headquartered in Vista, California. " (11/16/2018)
Has SeaSpine been receiving favorable news coverage?
Media headlines about SPNE stock have trended positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. SeaSpine earned a news impact score of 2.3 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days.
Who are some of SeaSpine's key competitors?
Some companies that are related to SeaSpine include K2M Group (KTWO), Cardiovascular Systems (CSII), Luminex (LMNX), Intersect ENT (XENT), Cryolife (CRY), Cerus (CERS), AngioDynamics (ANGO), SurModics (SRDX), OraSure Technologies (OSUR), Anika Therapeutics (ANIK), Antares Pharma (ATRS), LeMaitre Vascular (LMAT), Orthopediatrics (KIDS), Axonics Modulation Technologies (AXNX) and SI-Bone (SIBN).
Who are SeaSpine's key executives?
SeaSpine's management team includes the folowing people:
- Mr. Keith C. Valentine, Pres, CEO & Director (Age 51)
- Mr. John J. Bostjancic, Sr. VP, CFO & Treasurer (Age 48)
- Mr. Patrick L. Keran, VP, Gen. Counsel & Corp. Sec. (Age 47)
- Carrie Mendivil, Head of Investor Relations
- Mr. John J. Winge, VP of Sales (Age 52)
Who are SeaSpine's major shareholders?
SeaSpine's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.80%), Dimensional Fund Advisors LP (3.39%), Falcon Point Capital LLC (1.20%), Northern Trust Corp (0.99%), Geode Capital Management LLC (0.80%) and Millennium Management LLC (0.71%). Company insiders that own SeaSpine stock include John B Henneman III, Keith Bradley, Michael Fekete, Patrick L Keran and Stuart Essig. View Institutional Ownership Trends for SeaSpine.
Which major investors are selling SeaSpine stock?
SPNE stock was sold by a variety of institutional investors in the last quarter, including Hodges Capital Management Inc., Royce & Associates LP, Boston Partners, Eversept Partners LP and Acadian Asset Management LLC. Company insiders that have sold SeaSpine company stock in the last year include John B Henneman III, Keith Bradley and Stuart Essig. View Insider Buying and Selling for SeaSpine.
Which major investors are buying SeaSpine stock?
SPNE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Falcon Point Capital LLC, Millennium Management LLC, Essex Investment Management Co. LLC, Geode Capital Management LLC, Northern Trust Corp, Monarch Partners Asset Management LLC and Two Sigma Investments LP. Company insiders that have bought SeaSpine stock in the last two years include Michael Fekete and Stuart Essig. View Insider Buying and Selling for SeaSpine.
How do I buy shares of SeaSpine?
Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SeaSpine's stock price today?
One share of SPNE stock can currently be purchased for approximately $16.42.
How big of a company is SeaSpine?
SeaSpine has a market capitalization of $304.31 million and generates $131.81 million in revenue each year. The medical equipment provider earns $-32,110,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis. SeaSpine employs 327 workers across the globe.
What is SeaSpine's official website?
How can I contact SeaSpine?
SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-727-8399 or via email at [email protected]
MarketBeat Community Rating for SeaSpine (NASDAQ SPNE)
MarketBeat's community ratings are surveys of what our community members think about SeaSpine and other stocks. Vote "Outperform" if you believe SPNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
